{
  "nctId": "NCT05890586",
  "briefTitle": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)",
  "officialTitle": "ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications",
  "protocolDocument": {
    "nctId": "NCT05890586",
    "filename": "Prot_005.pdf",
    "label": "Study Protocol",
    "date": "2021-07-06",
    "uploadDate": "2023-08-02T10:35",
    "size": 1954755,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05890586/document/Prot_005.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 1331,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-06-08",
    "completionDate": "2022-09-04",
    "primaryCompletionDate": "2022-07-04",
    "firstSubmitDate": "2023-06-04",
    "firstPostDate": "2023-06-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Completed Informed Consent\n* Age ≥ 30 years old\n* Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening\n* Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell\n\nExclusion Criteria:\n\n* Prior diagnosis of COVID-19 infection (\\> 10 days from screening)\n* Current or recent (within 10 days of screening) hospitalization\n* Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo\n* Known contraindication(s) to study drug including prohibited concomitant medications",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "30 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Time to Sustained Recovery in Days",
        "description": "Time to sustained recovery was the number of days between receipt of study drug and the third of 3 consecutive days without symptoms. Participants who died, by definition, did not recover regardless of reported symptom freedom. The reported summary is the median survival time.",
        "timeFrame": "Up to 28 days"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Participants With Hospitalization or Death",
        "timeFrame": "Up to 28 days"
      },
      {
        "measure": "Number of Participants With Mortality",
        "timeFrame": "Up to 28 days"
      },
      {
        "measure": "Time to Mortality",
        "description": "Time to mortality was the number of days between drug receipt and death.",
        "timeFrame": "Up to 28 days"
      },
      {
        "measure": "Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death",
        "timeFrame": "Up to 28 days"
      },
      {
        "measure": "Number of Participants at Each Score on the COVID Clinical Progression Scale at Day 7",
        "description": "COVID Clinical Progression Scale is a scale of 0 to 8 where 0 = No clinical or virological evidence of infection, 1 = No limitation of activities, 2 = Limitation of activities, 3 = Hospitalized, no oxygen therapy, 4 = Hospitalized, on oxygen by mask or nasal prongs, 5 = Hospitalized, on non-invasive ventilation or high-flow oxygen, 6 = Hospitalized, on intubation and mechanical ventilation, 7 = Hospitalized, on ventilation + additional organ support (pressors, RRT, ECMO), 8 = Death.",
        "timeFrame": "Day 7"
      },
      {
        "measure": "Number of Participants at Each Score on the COVID Clinical Progression Scale at Day 14",
        "description": "COVID Clinical Progression Scale is a scale of 0 to 8 where 0 = No clinical or virological evidence of infection, 1 = No limitation of activities, 2 = Limitation of activities, 3 = Hospitalized, no oxygen therapy, 4 = Hospitalized, on oxygen by mask or nasal prongs, 5 = Hospitalized, on non-invasive ventilation or high-flow oxygen, 6 = Hospitalized, on intubation and mechanical ventilation, 7 = Hospitalized, on ventilation + additional organ support (pressors, RRT, ECMO), 8 = Death.",
        "timeFrame": "Day 14"
      },
      {
        "measure": "Number of Participants at Each Score on the COVID Clinical Progression Scale at Day 28",
        "description": "COVID Clinical Progression Scale is a scale of 0 to 8 where 0 = No clinical or virological evidence of infection, 1 = No limitation of activities, 2 = Limitation of activities, 3 = Hospitalized, no oxygen therapy, 4 = Hospitalized, on oxygen by mask or nasal prongs, 5 = Hospitalized, on non-invasive ventilation or high-flow oxygen, 6 = Hospitalized, on intubation and mechanical ventilation, 7 = Hospitalized, on ventilation + additional organ support (pressors, RRT, ECMO), 8 = Death.",
        "timeFrame": "Day 28"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Physical Function",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a higher score correlates to better outcome for physical function. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Fatigue",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for fatigue. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Pain",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for pain. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Depression",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20, where a lower score correlates to better outcome for depression. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Anxiety",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a lower score correlates to better outcome for anxiety.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Social",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a higher score correlates to better outcome for social roles and activities. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Quality of Life (QOL) as Measured by the PROMIS-29 - Sleep",
        "description": "The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. Raw score ranges from 4-20 where a lower score correlates to better outcome for sleep. Day 90 data to be reported by September 4, 2023.",
        "timeFrame": "Day 7, 14, 28, and 90"
      },
      {
        "measure": "Time Unwell in Days as Measured by the Symptom and Clinical Event Scale",
        "description": "The symptom and clinical event scale is a daily measurement that combines the global symptom burden scale with clinical events hospitalization and mortality. (No symptoms, mild symptoms, moderate symptoms, severe symptoms, hospitalized, deceased). Time unwell was the portion of follow-up (in days) that a participant was symptomatic, hospitalized, or deceased. The quantity is estimated from a Bayesian longitudinal ordinal regression model with covariate adjustment and weakly informative priors.",
        "timeFrame": "Up to 14 days"
      },
      {
        "measure": "Mean Days Benefit as Measured by the Symptom and Clinical Event Scale",
        "description": "The symptom and clinical event scale is a daily measurement that combines the global symptom burden scale with clinical events hospitalization and mortality. (No symptoms, mild symptoms, moderate symptoms, severe symptoms, hospitalized, deceased). The cumulative benefit of treatment A is the probability of experiencing a better outcome on treatment A compared to treatment B, summed over the days of follow-up. The difference between the cumulative benefit of treatment A and the cumulative benefit of treatment B is known as the difference in days benefit. Measure of dispersion is 95% credible interval.",
        "timeFrame": "Up to 14 days"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 16,
      "otherCount": 0,
      "totalCount": 17
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:37.324Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}